SOUTH SAN FRANCISCO, Calif., Sept. 30 /PRNewswire/ -- iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced that it has appointed Michael P. Smith as Vice President, Business Development and Wayne Montgomery, J.D., as Vice President, Legal Affairs and Intellectual Property.
"Mike brings to iPierian a breadth of strategic and transactional experience at both small and large companies. This will be invaluable as we enter therapeutic drug discovery collaborations with global biopharma companies, to achieve our goal of using iPSC technology to transform drug discovery and development," said Michael C. Venuti, Ph.D., CEO of iPierian. "Wayne has built and executed IP strategies spanning broad technology platforms to small molecule compositions. As we advance our foundational intellectual property for iPSC drug discovery, as well as move our lead therapeutic programs forward, his leadership will be a key part of creating value for iPierian. We are delighted to welcome these two executives with such strong experience and track records."
Michael Smith most recently served as Head of Business Development and Chief Financial Officer for Memory Pharmaceuticals, which was acquired by Roche. His experience includes a broad range of strategic transactions and initiatives including product and technology licenses, R&D collaborations, joint ventures, M&A, and strategic and portfolio planning. Prior to Memory, Mr. Smith served as Vice President of Business Development for QLT Inc., where he was responsible for all business development activities and corporate strategy. From 1998 to 2004, he was with Chiron Corporation most recently as Director of Corporate Development and held positions in several functions including strategic planning, corporate finance and commercial sales. Mr. Smith holds a B.S. from the Universit
|SOURCE iPierian, Inc.|
Copyright©2010 PR Newswire.
All rights reserved